The use of lymphocytapheresis as immunosuppressive therapy in the treatment of multiple sclerosis (MS) has been the focus of recent interest. Substantial numbers of patients have been treated in uncontrolled trials that have produced conflicting results as to effectiveness. Patients with a rapidly evolving chronic progressive course of disease do not seem to benefit from this treatment. Possibly, stabilization may occur in patients with a slower progressive course. However, definitive conclusions are not possible from current data. At this time lymphocytapheresis in the treatment of MS should be considered an experimental therapy, not used as a routine treatment. Lymphocytapheresis should be evaluated in a well-designed controlled clinical trial.
|Original language||English (US)|
|Number of pages||6|
|Journal||Plasma Therapy and Transfusion Technology|
|State||Published - 1982|
ASJC Scopus subject areas